XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Plans
6 Months Ended
Jun. 30, 2022
Equity Plans
12. EQUITY PLANS
2013 Equity Incentive Plan
In 2013, the Company adopted the 2013 Plan which provides for the grant of qualified incentive stock options (“ISO”) and nonqualified stock options (“NSO”), restricted stock, restricted stock units (“RSU”) or other awards to the Company’s employees, officers, directors, advisors, and outside consultants. After the Closing Date and consummation of the Business Combination effective March 2, 2022, no additional awards are being made pursuant to the 2013 Plan. Awards outstanding under the 2013 Plan will continue to be governed by such plan; however, the Company will not grant any further awards under the 2013 Plan.
2022 Equity Incentive Plan
In connection with the Business Combination (Note 3), the shareholders approved the Rigetti Computing, Inc. 2022 Equity Incentive Plan (the “2022 Plan”) in February, 2022, which became effective immediately upon the Closing Date. The 2022 Plan provides for the grant of ISOs, NSOs, stock appreciation rights, restricted stock awards (“RSA”), restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of Company’s affiliates. The aggregate number of shares of common stock reserved for future issuance under the 2022 Plan is 18,332,215 shares. The number of shares reserved for issuance under the 2022 Plan will automatically increase on January 1st of each year for a period of nine years commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to 5% of the common stock of all classes outstanding on December 31 of the preceding year; provided, however, that the board of directors of the Company may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock.
Stock Options
A summary of activity related to stock option is summarized as below (in thousands, except for share and per share data):
 
    
Number of

Options
    
Weighted-Average

Exercise Price
    
Weighted-average

contractual life
(in years)
    
Aggregate
Intrinsic
value
 
Outstanding – December 31, 2021
     11,468,275      $  0.36        8.1      $  46,839  
Granted
     —                               
Exercised
     (1,353,145    $ 0.27                 7,104  
Forfeited and expired
     (632,419    $ 0.27                    
    
 
 
    
 
 
    
 
 
    
 
 
 
Outstanding - June 30, 2022
     9,482,711      $ 0.35        7.7      $ 31,454  
    
 
 
    
 
 
    
 
 
    
 
 
 
Exercisable - June 30, 2022
     5,874,426      $ 0.39        7.7      $ 19,258  
The weighted-average grant date fair value of options granted during the six months ended June 30, 2021 was $0.09 per share. No new option grants were issued during the six months ended June 30, 2022. The total intrinsic value of options exercised during the six months ended June 30, 2022 and June 30, 2021 is $7.1 million and $0.5 million, respectively.
As of June 30, 2022, there was $1.9 million of unrecognized compensation cost related to
non-vested
stock options granted under the Plan, which is expected to be recognized over a weighted-average period of approximately 1.7 years.
 
31
Restricted Stock Units
A summary of activity related to RSUs is summarized as below:
 
    
RSUs
    
Weighted Average
Fair Value
Per Share
 
Balance at December 31, 2021
     5,388,455           
Granted
     9,885,413      $ 4.89  
Vested
     (2,630,699         
Forfeited
     (792,643         
    
 
 
          
Balance at June 30, 2022
     11,850,526           
    
 
 
          
On March 2, 2022, the performance condition of all outstanding RSUs was met due to the closing of the Business Combination. As a result, the Company recorded a cumulative
catch-up
compensation expense for the vesting period that has been satisfied as of March 2, 2022 and continues amortizing compensation expenses for unvested RSUs over their remaining vesting period.
Total fair value of the RSUs vested during the six months ending June 30, 2022 and 2021 was $12.9 million and $0 respectively.
Stock-based compensation expense related to RSUs granted to employees was $10.7 million and $21.9 million for the three and six months ended June 30, 2022, respectively. Stock-based compensation expense was $0 for the three and six months ended June 30, 2021. As of June 30, 2022, the unrecognized compensation expense related to unvested RSUs was approximately $49.1 million which is expected to be recognized over a weighted- average period of approximately 2.24 years.
Restricted Stock Awards
During the first six months ended June 30, 2022, 120,000 restricted stock awards (“RSAs”) were issued and vested immediately on the grant date as part of transaction bonuses in recognition of efforts in connection with the Business Combination. The total compensation expense related to RSAs was $623 thousand for the three and six months ended June 30, 2022, respectively. The compensation expense was $0 for the three and six months ended June 30, 2021.
The table below summarizes the total stock compensation expenses for the three and six months ended June 30, 2022 and 2021 (in thousands):
 
    
3 Months Ended
    
6 Months Ended
 
    
June 30,
    
June 30,
 
    
2022
    
2022
 
Research and development
   $ 2,209      $ 4,598  
Sales and marketing expenses
     256        697  
General and administrative expenses
     8,576        17,227  
    
 
 
    
 
 
 
Total Stock Compensation Expenses
   $ 11,041      $ 22,522  
    
 
 
    
 
 
 
 
    
3 Months Ended
    
6 Months Ended
 
    
June 30,
    
June 30,
 
    
2021
    
2021
 
Research and development
   $ 299      $ 638  
Sales and marketing expenses
     29        61  
General and administrative expenses
     193        419  
    
 
 
    
 
 
 
Total Stock Compensation Expenses
   $ 521      $ 1,118  
    
 
 
    
 
 
 
 
Fair Value of Common Stock and Options
The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that uses the assumptions noted in the table below. Expected volatility for the Company’s common stock was determined based on an average of the historical volatility of a peer group of similar public companies. The expected term of options granted was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk-free rate is based upon the U.S. Treasury yield curve in effect at the time of grant for the period equivalent to the expected life of the option.
In determining the exercise prices for options granted, the Company’s board of directors has considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined by the board of directors at each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company’s financial position and historical financial performance, the status of technological developments within the Company’s products, the composition and ability of the current engineering and management team, an evaluation or benchmark of the Company’s competition, the current business climate in the marketplace, the illiquid nature of the common stock,
arm’s-length
sales of the Company’s capital stock (including redeemable convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others.
The Company did not grant any stock option awards during the six months ended June 30, 2022. The range of assumptions used in the Black-Scholes option-pricing model for options issued to employees during the six months ended June 30, 2021, are as follows:
 
    
June 30,
 
    
2021
 
Expected volatility
     46.8
Weighted-average risk-free interest rate
     1.07
Expected dividend yield
     0
Expected term (in years)
     6.1 years  
Exercise price
   $ 0.21